VCANBIO(SH:600645) Xin Lang Cai Jing·2025-09-09 10:28Core Viewpoint - The company Zhongyuan Xiehe has received approval from the National Medical Products Administration for clinical trials of VUM02 injection for the treatment of severe/critical pneumonia, marking a significant step in the development of a novel cell therapy product [1] Company Summary - The full subsidiary Wuhan Guanggu Zhongyuan Pharmaceutical Co., Ltd. has been granted a "Drug Clinical Trial Approval Notice" for VUM02 injection [1] - VUM02 injection is derived from umbilical cord mesenchymal stem cells (UC-MSC) obtained from selected healthy newborns, indicating a unique source for the new drug [1] - The total research and development investment for the related project amounts to RMB 16.5624 million [1] Industry Summary - Currently, there are no similar cell therapies approved for the treatment of severe/critical pneumonia globally, highlighting a potential market opportunity for VUM02 injection [1]